These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19346023)

  • 1. The impact of generic substitution on the turnover and gross margin of pharmaceutical companies a survey 1 year and 5 years after the introduction of generic substitution in Finland.
    Timonen J; Karttunen P; Bengtström M; Ahonen R
    Health Policy; 2009 Oct; 92(2-3):116-23. PubMed ID: 19346023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of generic substitution on price competition in Finland.
    Aalto-Setälä V
    Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of generic substitution on the activities of pharmaceutical companies - a survey from the companies' perspective one year and five years after the introduction of generic substitution in finland.
    Timonen J; Bengtström M; Karttunen P; Ahonen R
    BMC Clin Pharmacol; 2010 Oct; 10():15. PubMed ID: 20964869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of being first: evidence from Canadian generic pharmaceuticals.
    Hollis A
    Health Econ; 2002 Dec; 11(8):723-34. PubMed ID: 12457372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folly or volley? Will a dollar $4 pill finally open the healthcare market to competitive pricing?
    Sturm AC
    Healthc Financ Manage; 2006 Nov; 60(11):120-2. PubMed ID: 17094287
    [No Abstract]   [Full Text] [Related]  

  • 6. Who's really raising drug prices?
    Zagorin A
    Time; 1999 Mar; 153(9):46-8. PubMed ID: 10346086
    [No Abstract]   [Full Text] [Related]  

  • 7. Price regulation and generic competition in the pharmaceutical market.
    Dalen DM; Strøm S; Haabeth T
    Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of generic drug competition on the price of prescription drugs in Ontario.
    Lexchin J
    CMAJ; 1993 Jan; 148(1):35-8. PubMed ID: 8439888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. White paper. The five myths of generic competition. A Pharma Matters report. March 2009.
    Drug News Perspect; 2009 Apr; 22(3):171-5. PubMed ID: 19440560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A survey exploring knowledge and perceptions of general practitioners towards the use of generic medicines in the northern state of Malaysia.
    Chua GN; Hassali MA; Shafie AA; Awaisu A
    Health Policy; 2010 May; 95(2-3):229-35. PubMed ID: 20044165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
    McManus P; Birkett DJ; Dudley J; Stevens A
    Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indian generics companies go on spending spree.
    Jayaraman KS
    Nat Rev Drug Discov; 2005 Aug; 4(8):616-7. PubMed ID: 16106583
    [No Abstract]   [Full Text] [Related]  

  • 14. The Eleventh Circuit holds that agreements in which pharmaceutical companies pay generic companies not to compete may be valid.
    Garrigues A
    J Law Med Ethics; 2004; 32(1):181-4. PubMed ID: 15152443
    [No Abstract]   [Full Text] [Related]  

  • 15. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
    Kong Y
    Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are we living in the end of the blockbuster drug era?
    Debnath B; Al-Mawsawi LQ; Neamati N
    Drug News Perspect; 2010 Dec; 23(10):670-84. PubMed ID: 21180653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generics market in Greece: the pharmaceutical industry's beliefs.
    Geitona M; Zavras D; Hatzikou M; Kyriopoulos J
    Health Policy; 2006 Nov; 79(1):35-48. PubMed ID: 16386326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [What drug companies actually do].
    Tonby K
    Tidsskr Nor Laegeforen; 2007 Jun; 127(13):1806. PubMed ID: 17599137
    [No Abstract]   [Full Text] [Related]  

  • 19. Congress works to permit 'biosimilar' drugs very soon.
    Carroll J
    Manag Care; 2009 Apr; 18(4):7-8. PubMed ID: 19472559
    [No Abstract]   [Full Text] [Related]  

  • 20. Competition and the Reference Pricing Scheme for pharmaceuticals.
    Ghislandi S
    J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.